Drug Profile
Melphalan intraocular injection - EyePoint Pharmaceuticals
Latest Information Update: 03 Dec 2021
Price :
$50
*
At a glance
- Originator EyePoint Pharmaceuticals; Icon Bioscience
- Developer Icon Bioscience
- Class Antineoplastics; Aromatic amino acids; Myeloablative agonists; Nitrogen mustard compounds; Small molecules
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinoblastoma
Most Recent Events
- 28 Mar 2018 Icon Bioscience has been acquired by EyePoint Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Retinoblastoma in USA (Intraocular, Controlled release)
- 03 Jan 2013 Icon Bioscience's controlled-release intraocular injection formulation of Melphalan receives Orphan Drug status for Retinoblastoma in USA